Synthesis and evaluation of biological activity of newly designed hydroxamates as potential HDAC inhibitors

Investor logo

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Pharmacy. Official publication website can be found on muni.cz.
Authors

ONUŠČÁKOVÁ Magdaléna PÍŽOVÁ Hana KAUEROVÁ Tereza KOLLÁR Peter BOBÁĽ Pavel

Year of publication 2023
Type Appeared in Conference without Proceedings
MU Faculty or unit

Faculty of Pharmacy

Citation
Description Histone deacetylases (HDACs) are metalloenzymes involved in the regulation of fundamental cellular processes, such as cell cycle progression, differentiation, and tumorigenesis. The abnormal function of HDACs can induce severe human diseases, including cancer, pulmonary disease, and neurodegenerative disorders.1 Histone deacetylase inhibitors (HDACi) represent a relatively new generation of drugs with the ability to affect the expression of specific genes, which can repair controlled proliferation or damage apoptotic processes in tumor cells
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.